Conatus
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Conatus and buy or sell other stocks, ETFs, and their options commission-free!About CNAT
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases.
CEOSteven J. Mento, PhD
CEOSteven J. Mento, PhD
Employees—
Employees—
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2005
Founded2005
Employees—
Employees—
CNAT Key Statistics
Market cap42.70K
Market cap42.70K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume550.56
Average volume550.56
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.30
52 Week high$0.30
52 Week low$0.0002
52 Week low$0.0002
People also own
Based on the portfolios of people who own CNAT. This list is generated using Robinhood data, and it’s not a recommendation.